© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
June 02, 2009
Early chemotherapy for relapsed ovarian cancer based on serial monitoring of CA-125 levels failed to improve overall survival or quality of life compared with delayed therapy according to clinical signs and symptoms of relapse in a large European trial.
Noah Rindos, MD, Talks Fibroids, Adenomyosis and Pregnancy
Kausik Ray, MD: A Risk-Based Look at LDL Cholesterol Lowering
Jennifer Green, MD: Outcomes, Impact of SGLT2i, GLP-1 RA Combination Therapy